Takeda (TAK) Q3 FY26 earnings call

Takeda delivered a quarter marked by significant pipeline advancements, with three late-stage assets showing positive Phase III data and preparing for launch, poised to drive future growth. Despite a revised full-year revenue outlook due to VYVANSE generic erosion, the company maintained profit guidance through disciplined cost management. The leadership transition to CEO-elect Julie Kim is underway, with new organizational structures implemented to enhance competitiveness and accelerate upcoming launches, while navigating market challenges like the IRA and China demand fluctuations.